RGLS — Regulus Therapeutics Share News
0.000.00%
Last trade - 00:00- $563.57m
- $498.20m
Brief: Regulus Therapeutics Announces Completion Of Enrollment In Second Cohort Of Phase 1B Trial Of Rgls8429 In A Kidney Disease Study
Regulus Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Regulus Therapeutics Inc expected to post a loss of 41 cents a share - Earnings Preview
Brief: Regulus Therapeutics Says First Patient Dosed In Second Cohort Of Phase 1b MAD Clinical Trial Of RGLS8429
Brief: Regulus Therapeutics Announces Appointment Of Preston Klassen, M.D. To Its Board Of Directors
Brief: Regulus Therapeutics Announces Update On Preclinical Studies In Amyotrophic Lateral Sclerosis In Collaboration With Researchers From Harvard's Brigham And Women's Hospital
Brief: Regulus Therapeutics Advances To Cohort 2 Of Phase 1B Multiple-Ascending Dose Clinical Trial Of Rgls8429 For The Treatment Of Autosomal Dominant Polycystic Kidney Disease
Regulus Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Regulus Therapeutics Reports First Quarter 2023 Financial Results And Recent Updates
Regulus Therapeutics Inc expected to post a loss of 44 cents a share - Earnings Preview
Brief: Regulus Therapeutics Announces $15 Million Private Placement Of Equity
Brief: Regulus Therapeutics Announces Completion Of Enrollment In First Cohort Of Phase 1B Multiple-Ascending Dose Clinical Trial Of RGLS8429
Brief: Regulus Therapeutics Reports Fourth Quarter Results
Regulus Therapeutics Inc expected to post a loss of 51 cents a share - Earnings Preview
Brief: Regulus Therapeutics Inc - Sanofi Delivered Written Notice To Co To Terminate Second Amended, Restated Collaboration, License Agreement
Regulus Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Regulus Therapeutics Reports Third Quarter 2022 Financial Results And Recent Updates
Regulus Therapeutics Inc expected to post a loss of 49 cents a share - Earnings Preview
Regulus Therapeutics Inc expected to post a loss of 47 cents a share - Earnings Preview